Sorrento Therapeutics Inc
Change company Symbol lookup
Select an option...
SRNE Sorrento Therapeutics Inc
CPLP Capital Product Partners LP
BVNNF Bevcanna Enterprises Inc
OCUL Ocular Therapeutix Inc
GOOG Alphabet Inc
BAC Bank of America Corp
ED Consolidated Edison Inc
FRAN Francesca's Holdings Corp
CWBHF Charlotte's Web Holdings Inc
SALM Salem Media Group Inc
Go

Health Care : Biotechnology | Small Cap Value
Company profile

Sorrento Therapeutics, Inc. is a clinical-stage and commercial biopharma company. The Company operates through two segments: Sorrento Therapeutics and Scilex. The Sorrento Therapeutics segment is organized around its Immune-Oncology therapeutic area, leveraging its G-MAB antibody library and targeted delivery modalities to generate the next generation of cancer therapeutics. These modalities include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy (DAR-T), antibody-drug conjugates (ADC), as well as bispecific antibody approaches. Additionally, Sorrento Therapeutics segment also includes Sofusa, a drug delivery technology that delivers biologics directly into the lymphatic system to potentially achieve improved efficacy and fewer adverse effects than standard parenteral immunotherapy. The Scilex segment is organized around its non-opioid pain management operations.

Closing Price
$9.43
Day's Change
-0.05 (-0.53%)
Bid
--
Ask
--
B/A Size
--
Day's High
9.46
Day's Low
8.64
Volume
(Average)
Volume:
35,168,066

10-day average volume:
34,365,421
35,168,066

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Sorrento Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 27, 2020 - SRNE

2:29 pm ET July 24, 2020 (Newsfile) Print

New York, New York--(Newsfile Corp. - July 24, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired securities of Sorrento Therapeutics, Inc. ("Sorrento") (NASDAQ: SRNE) between May 15, 2020 and May 22, 2020. You are hereby notified that a securities class action lawsuit has been commenced in the the United States District Court for the Southern District of California. To get more information go to:

https://www.zlk.com/pslra-1/sorrento-therapeutics-inc-information-request-form?prid=8166&wire=5

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. There is no cost or obligation to you.

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/7091/60480_936334_logo.jpg

The complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) the Company's initial finding of "100% inhibition" in an in vitro virus infection will not necessarily translate to to success or safety in vivo, or in person; (ii) the Company's finding was not a "cure" for COVID-19; and (ii) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

If you suffered a loss in Sorrento you have until July 27, 2020 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

55 Broadway, 10th Floor

New York, NY 10006

jlevi@levikorsinsky.com

Tel: (212) 363-7500

Fax: (212) 363-7171

www.zlk.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/60480

comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.